Achillion's hepatitis C drug cures all patients in mid-stage trial

Fri Aug 15, 2014 8:06am EDT

Aug 15 (Reuters) - Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.

The mid-stage trial tested Achillion's drug, ACH-3102, in 12 patients in combination with Gilead Sciences Inc's Sovaldi, also known as sofosbuvir.

Achillion said it would begin treating 12 additional patients for six weeks with a once-daily dose of ACH-3102 and sofosbuvir.

The trial excluded the older hepatitis C drug ribavirin, which can cause rashes, anemia and other side effects.

Achillion shares rose about 10 percent to $9.25 in premarket trading. (Reporting by Anand Basu in Bangalore; Editing by Simon Jennings)

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article